BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc. (OTCBB: URGP), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, was issued an additional patent relating to Urethral Suppositories by the U.S. Patent and Trademark Office. This patent expires August 30, 2021.
The patent number 7,267,670 broadens protection for Urigen’s urethral suppository program to include a reinforced female urethral suppository platform.
